Weighted Average Number of Shares Outstanding, Diluted of iTeos Therapeutics, Inc. from 30 Sep 2020 to 30 Jun 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
iTeos Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Sep 2020 to 30 Jun 2025.
  • iTeos Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Jun 2025 was 43,564,573, a 9.7% increase year-over-year.
  • iTeos Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 40,474,385, a 13% increase from 2023.
  • iTeos Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 35,763,520, a 5.3% decline from 2022.
  • iTeos Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 37,766,507, a 0.02% decline from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

iTeos Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 43,564,573 +3,865,520 +9.7% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 43,241,341 +7,398,225 +21% 01 Jan 2025 31 Mar 2025 10-Q 28 Apr 2025 2025 Q1
Q4 2024 40,474,385 +4,710,865 +13% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
Q3 2024 43,135,464 +7,352,304 +21% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 39,699,053 +3,930,101 +11% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 35,843,116 +127,079 +0.36% 01 Jan 2024 31 Mar 2024 10-Q 28 Apr 2025 2025 Q1
Q4 2023 35,763,520 -2,002,987 -5.3% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 35,783,160 -1,872,580 -5% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 35,768,952 -1,866,876 -5% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 35,716,037 -2,419,920 -6.3% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 37,766,507 -8,283 -0.02% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 37,655,740 +173,651 +0.46% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 37,635,828 +2,515,876 +7.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 38,135,957 +3,049,295 +8.7% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 37,774,790 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
Q3 2021 37,482,089 +13,132,867 +54% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 35,119,952 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 35,086,662 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 24,349,222 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3

iTeos Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 40,474,385 +4,710,865 +13% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
2023 35,763,520 -2,002,987 -5.3% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
2022 37,766,507 -8,283 -0.02% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2021 37,774,790 +22,694,524 +150% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 15,080,266 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.